Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756221 | 1.00 | NPSR1 (0.48) | NPSR1NOS3NOS1NOS2KDM4E | |
| SCHEMBL28033848 | 0.82 | ALDH1A1 (0.49) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL31252858 | 0.81 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL8320350 | 0.81 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL1428189 | 0.81 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL2372967 | 0.81 | NPSR1 (0.52) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL25359629 | 0.80 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL15390591 | 0.80 | KDM4E (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL1268827 | 0.80 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL29549957 | 0.79 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4293029-B1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20240182492-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| CN-116888125-B | TYK2 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4293029-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| CN-116888125-A | TYK2 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022171166-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182492-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | EZH2, EED, EZH1 | NPSR1 3315/4885NOS3 4347/4885NOS1 3800/4885 |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | NPSR1 933/4885NOS3 1474/4885NOS1 1444/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | NPSR1 321/4885NOS3 759/4885NOS1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.